Compare FBK & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBK | HAE |
|---|---|---|
| Founded | 1906 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.8B |
| IPO Year | 2016 | 1996 |
| Metric | FBK | HAE |
|---|---|---|
| Price | $56.68 | $76.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $64.50 | ★ $84.13 |
| AVG Volume (30 Days) | 361.9K | ★ 871.5K |
| Earning Date | 04-13-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.10 | ★ 2.05 |
| Revenue | N/A | ★ $910,373,000.00 |
| Revenue This Year | $41.72 | N/A |
| Revenue Next Year | $7.21 | $5.23 |
| P/E Ratio | $51.11 | ★ $36.59 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $45.58 | $47.32 |
| 52 Week High | $62.37 | $87.32 |
| Indicator | FBK | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 60.96 | 60.56 |
| Support Level | $56.78 | $72.04 |
| Resistance Level | $60.20 | $80.90 |
| Average True Range (ATR) | 0.93 | 2.68 |
| MACD | 0.11 | -0.51 |
| Stochastic Oscillator | 89.49 | 54.12 |
FB Financial Corp is a bank holding company. The company through its wholly-owned bank subsidiary provides commercial and consumer banking services to clients in select markets in Tennessee, North Alabama, and North Georgia. The company segment includes Banking and Mortgage. It generates majority of revenue from the Banking segment which provides a full range of deposit and lending products and services to corporate, commercial, and consumer customers. The Mortgage segment includes the servicing of residential mortgage loans and the packaging and securitization of loans to governmental agencies.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.